NKTR Nektar Therapeutics - Common Stock
$72,34
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 14, 2026
Zakres 52 tyg.
$25–$109
56% of range
Ocena Analityków
BUY
17 analysts
Cena Docelowa
$153
+112% upside
P/E (TTM)
-10.8
ROE
-500.1%
Marża Zysku Netto
-297.1%
O Nektar Therapeutics - Common Stock Przegląd firmy z Wikipedii
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Czytaj więcej
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
NKTR Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$72.34
Kapitalizacja Rynkowa
$2.13B
P/E (TTM)
-10.8
EPS (TTM)
$-9.73
Przychody (TTM)
$55M
Stopa dywidendy
—
ROE
-500.1%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$25 – $109
NKTR Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$55M
2016-12-31
→
2025-12-31
EPS
$-9.73
2016-12-31
→
2025-12-31
Wolny przepływ pieniężny
$-209M
2016-12-31
→
2025-12-31
Marże
-297.1%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
NKTR
Mediana porównawcza
P/E (TTM)
-10.8
29.4
P/S (TTM)
38.6
4.9
P/B
23.7
6.5
Price / FCF (Cena / FCF)
-10.2
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
NKTR
Mediana porównawcza
Operating Margin (Marża Operacyjna)
-253.7%
—
Net Profit Margin (Marża Zysku Netto)
-297.1%
-9.0%
ROA
-56.2%
-8.2%
ROE
-500.1%
-19.4%
ROIC
-155.8%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
NKTR
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
5.0
3.6
Quick Ratio (Wskaźnik Szybkości)
0.3
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
NKTR
Mediana porównawcza
Revenue YoY (Przychody R/R)
-43.9%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
-15.7%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
-18.4%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
NKTR
Mediana porównawcza
NKTR Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
17 analityków
- Mocne kupno 7 41,2%
- Kup 8 47,1%
- Trzymaj 2 11,8%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
9 analityków · 2026-08-16
Mediana
$151.00
← Poniżej wszystkich celów
$72.34
Niski
$80.00
Wysoki
$192.00
Średni cel
$151.00
+108,7%
Średnia cel
$153.22
+111,8%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.21%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-1.23 | $-2.02 | 0.79% |
| 31 marca 2026 | $-1.82 | $-1.63 | -0.19% |
| 31 grudnia 2025 | $-1.78 | $-2.52 | 0.74% |
| 30 września 2025 | $-1.87 | $-2.74 | 0.87% |
| 30 czerwca 2025 | $-2.95 | $-3.10 | 0.15% |
| 31 marca 2025 | $-3.60 | $-2.51 | -1.1% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | — |
| ALMS | — | -3.4 | — | -1011.8% | -61.9% | — |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | — |
| SUPN | $2.86B | -73.1 | 8.6% | -5.4% | -3.6% | — |
| ATAI | $223M | -1.4 | -1.9% | -48464.0% | -83.1% | — |
| TRVI | $1.61B | -39.1 | — | — | -22.4% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| AMLX | $1.33B | -7.9 | -77.1% | — | -61.2% | — |
| PBH | $3.33B | 15.2 | -4.3% | 17.5% | 10.2% | 54.7% |
| RAPP | $1.45B | -10.6 | — | — | -29.8% | — |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
Bilans 24
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
Przepływy pieniężne 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
Płynność i wypłacalność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
Bilans 23
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
Przepływy pieniężne 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
Płynność i wypłacalność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44M | $44M | · | $58M | $69M | $80M | · | $93M | $90M | $88M | · | $90M | $87M | $92M | · | $95M | |
| Net Income TTM | $-163M | $-173M | · | $-165M | $-182M | $-177M | · | $-172M | $-186M | $-271M | · | $-293M | $-406M | $-446M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -8.9 | -7.0 | · | -7.4 | -2.7 | -1.5 | · | -2.8 | -4.2 | -9.8 | · | -5.8 | -4.0 | -4.4 | · | -0.1 | |
| P/S | 32.4 | 33.1 | · | 19.4 | 4.6 | 23.8 | · | 38.5 | 38.1 | 29.1 | · | 19.1 | 18.9 | 21.7 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| P / FCF | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.3 | · | · | · | -38.0 | · | · | |
| Earnings Yield | -11.3% | -14.3% | · | -13.6% | -37.2% | -67.2% | · | -35.1% | -24.0% | -10.2% | · | -17.2% | -24.8% | -22.7% | · | -1649.3% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $55M | $98M | $90M | $92M | $102M |
| Marża Operacyjna % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Zysk netto | $-164M | $-119M | $-276M | $-368M | $-524M |
| Rozwodniony EPS | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| Wskaźnik Szybkości | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-209M | $-177M | $-193M | $-310M | $-428M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 269 emitentów · $2.1B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 88 (+20 vs poprzedni kw.) | 41 (+9 vs poprzedni kw.) | 91 (+21 vs poprzedni kw.) | 48 (-8 vs poprzedni kw.) | +8.5M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Two Seas Capital LP | $215 868 856 | 3 092 234 | 10,35% | Akcje |
| FMR LLC | $192 088 149 | 2 751 585 | 9,21% | Akcje |
| BVF INC/IL | $166 920 946 | 2 391 075 | 8,00% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $104 495 029 | 1 496 849 | 5,01% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $83 911 899 | 1 202 004 | 4,02% | Akcje |
| Vestal Point Capital, LP | $69 810 000 | 1 000 000 | 3,35% | Akcje |
| STATE STREET CORP | $63 504 691 | 909 679 | 3,04% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57 502 497 | 823 700 | 2,76% | Opcja kupna |
| Prosight Management, LP | $56 546 100 | 810 000 | 2,71% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $52 759 799 | 755 586 | 2,53% | Akcje |
| ARMISTICE CAPITAL, LLC | $50 542 440 | 724 000 | 2,42% | Akcje |
| GILDER GAGNON HOWE & CO LLC | $41 946 944 | 600 873 | 2,01% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $33 377 557 | 478 120 | 1,60% | Akcje |
| BRAIDWELL LP | $33 063 203 | 473 617 | 1,59% | Akcje |
| Sofinnova Investments, Inc. | $32 933 775 | 471 763 | 1,58% | Akcje |
| Woodline Partners LP | $32 871 784 | 470 875 | 1,58% | Akcje |
| ORBIMED ADVISORS LLC | $32 485 804 | 465 346 | 1,56% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27 540 045 | 394 500 | 1,32% | Opcja sprzedaży |
| EMERALD ADVISERS, LLC | $27 236 930 | 390 158 | 1,31% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24 331 577 | 348 540 | 1,17% | Akcje |
| DAFNA Capital Management LLC | $22 226 108 | 318 380 | 1,07% | Akcje |
| Deep Track Capital, LP | $20 943 000 | 300 000 | 1,00% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19 893 826 | 284 971 | 0,95% | Akcje |
| 22NW, LP | $19 624 638 | 281 115 | 0,94% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19 475 384 | 278 977 | 0,93% | Akcje |
| PRIMECAP MANAGEMENT CO/CA/ | $19 047 658 | 272 850 | 0,91% | Akcje |
| Nearwater Capital Markets, Ltd | $18 255 315 | 261 500 | 0,88% | Akcje |
| BARCLAYS PLC | $17 968 815 | 257 396 | 0,86% | Akcje |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17 842 528 | 255 587 | 0,86% | Akcje |
| ADAR1 Capital Management, LLC | $17 046 485 | 244 184 | 0,82% | Akcje |
| Creek Drive Management Group LLC | $16 963 830 | 243 000 | 0,81% | Akcje |
| SEVEN GRAND MANAGERS, LLC | $16 754 400 | 240 000 | 0,80% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $16 724 731 | 239 575 | 0,80% | Akcje |
| NORGES BANK | $15 030 093 | 215 300 | 0,72% | Akcje |
| Bronte Capital Management Pty Ltd. | $13 852 678 | 198 434 | 0,66% | Akcje |
| TWO SIGMA ADVISERS, LP | $13 039 744 | 308 414 | 0,63% | Akcje |
| CITADEL ADVISORS LLC | $12 251 655 | 175 500 | 0,59% | Opcja sprzedaży |
| GREAT POINT PARTNERS LLC | $12 216 750 | 175 000 | 0,59% | Akcje |
| Caption Management, LLC | $11 944 491 | 171 100 | 0,57% | Opcja kupna |
| MILLENNIUM MANAGEMENT LLC | $11 867 700 | 170 000 | 0,57% | Opcja kupna |
| CITADEL ADVISORS LLC | $11 434 878 | 163 800 | 0,55% | Opcja kupna |
| AMERIPRISE FINANCIAL INC | $11 050 085 | 158 288 | 0,53% | Akcje |
| Quinn Opportunity Partners LLC | $10 686 236 | 153 076 | 0,51% | Akcje |
| GOLDMAN SACHS GROUP INC | $10 011 801 | 143 415 | 0,48% | Akcje |
| Rhenman & Partners Asset Management AB | $9 860 662 | 141 250 | 0,47% | Akcje |
| Qube Research & Technologies Ltd | $9 111 671 | 130 521 | 0,44% | Akcje |
| LMR Partners LLP | $9 075 300 | 130 000 | 0,44% | Opcja sprzedaży |
| Soleus Capital Management, L.P. | $8 960 951 | 128 362 | 0,43% | Akcje |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $8 570 364 | 122 767 | 0,41% | Akcje |
| Stonepine Capital Management, LLC | $8 422 856 | 120 654 | 0,40% | Akcje |
| SummitTX Capital, L.P. | $7 883 923 | 112 934 | 0,38% | Akcje |
| APEIRON CAPITAL Ltd | $7 429 948 | 106 431 | 0,36% | Akcje |
| CITIGROUP INC | $7 034 824 | 100 771 | 0,34% | Akcje |
| ING GROEP NV | $6 981 000 | 100 000 | 0,33% | Akcje |
| LMR Partners LLP | $6 981 000 | 100 000 | 0,33% | Akcje |
| Susquehanna Portfolio Strategies, LLC | $6 685 704 | 95 770 | 0,32% | Akcje |
| Militia Capital Management LLC | $6 282 900 | 90 000 | 0,30% | Akcje |
| ACT CAPITAL MANAGEMENT, LLC | $6 234 033 | 89 300 | 0,30% | Akcje |
| Tetragon Partners GP Ltd | $6 073 191 | 86 996 | 0,29% | Akcje |
| READYSTATE ASSET MANAGEMENT LP | $5 941 529 | 85 110 | 0,28% | Akcje |
| Birchview Capital, LP | $5 654 610 | 81 000 | 0,27% | Akcje |
| BlackRock, Inc. | $5 444 412 | 77 989 | 0,26% | Akcje |
| GROUP ONE TRADING LLC | $4 912 600 | 70 371 | 0,24% | Akcje |
| ALGERT GLOBAL LLC | $4 686 345 | 67 130 | 0,22% | Akcje |
| Moody Aldrich Partners LLC | $4 477 264 | 64 135 | 0,21% | Akcje |
| WOLVERINE TRADING, LLC | $4 330 620 | 73 500 | 0,21% | Opcja sprzedaży |
| Swiss National Bank | $4 300 296 | 61 600 | 0,21% | Akcje |
| F/m Investments LLC | $4 229 439 | 60 585 | 0,20% | Akcje |
| BANK OF AMERICA CORP /DE/ | $4 227 764 | 60 561 | 0,20% | Akcje |
| ExodusPoint Capital Management, LP | $4 084 374 | 58 507 | 0,20% | Akcje |
| Trexquant Investment LP | $3 956 831 | 56 680 | 0,19% | Akcje |
| K2 PRINCIPAL FUND, L.P. | $3 522 962 | 50 465 | 0,17% | Akcje |
| WOLVERINE TRADING, LLC | $3 403 101 | 57 758 | 0,16% | Akcje |
| RHUMBLINE ADVISERS | $3 008 381 | 43 094 | 0,14% | Akcje |
| MORGAN STANLEY | $2 943 050 | 42 158 | 0,14% | Akcje |
| Voleon Capital Management LP | $2 850 901 | 40 838 | 0,14% | Akcje |
| Anson Funds Management LP | $2 829 748 | 40 535 | 0,14% | Akcje |
| Atom Investors LP | $2 828 631 | 40 519 | 0,14% | Akcje |
| WOLVERINE TRADING, LLC | $2 792 808 | 47 400 | 0,13% | Opcja kupna |
| Burkehill Global Management, LP | $2 792 400 | 40 000 | 0,13% | Akcje |
| NOMURA HOLDINGS INC | $2 792 400 | 40 000 | 0,13% | Opcja sprzedaży |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $2 708 768 | 38 802 | 0,13% | Akcje |
| NOMURA HOLDINGS INC | $2 698 645 | 38 657 | 0,13% | Akcje |
| Jefferies Financial Group Inc. | $2 664 299 | 38 165 | 0,13% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $2 590 200 | 36 000 | 0,12% | Akcje |
| Connor, Clark & Lunn Investment Management Ltd. | $2 575 780 | 36 897 | 0,12% | Akcje |
| ALPS ADVISORS INC | $2 386 664 | 34 188 | 0,11% | Akcje |
| FRED ALGER MANAGEMENT, LLC | $2 350 712 | 33 673 | 0,11% | Akcje |
| TUDOR INVESTMENT CORP ET AL | $2 345 616 | 33 600 | 0,11% | Opcja kupna |
| Bank of New York Mellon Corp | $2 306 522 | 33 040 | 0,11% | Akcje |
| Ghisallo Capital Management LLC | $2 233 920 | 32 000 | 0,11% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2 063 670 | 28 682 | 0,10% | Akcje |
| Blackstone Inc. | $2 002 011 | 28 678 | 0,10% | Akcje |
| KVP Capital Advisors, LP | $1 877 889 | 26 900 | 0,09% | Akcje |
| Ishara Investments LP | $1 860 437 | 26 650 | 0,09% | Akcje |
| Erste Asset Management GmbH | $1 830 920 | 28 000 | 0,09% | Akcje |
| Caption Management, LLC | $1 822 041 | 26 100 | 0,09% | Opcja sprzedaży |
| WINTON GROUP Ltd | $1 808 079 | 25 900 | 0,09% | Akcje |
| K2 PRINCIPAL FUND, L.P. | $1 745 250 | 25 000 | 0,08% | Opcja kupna |
| Empowered Funds, LLC | $1 636 416 | 23 441 | 0,08% | Akcje |
Insiderzy spółki 40 insiderów · 20 dyrektorzy generalni · 18 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 24 lipca 2026 A | 55 045 | 0 | 20 | $-2 224 055 |
| Jillian B. Thomsen | Chief Financial Officer | 16 lutego 2023 S | 313 497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16 maja 2022 S | 312 905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23 sierpnia 2007 A | — | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14 maja 2007 A | 6 000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 4 marca 2004 S | 743 904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16 sierpnia 2019 S | 162 759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 1 lutego 2010 A | — | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 24 lipca 2026 A | 9 756 | 0 | 12 | $-1 052 364 |
| Mark Andrew Wilson | Chief Legal Officer | 21 listopada 2025 A | 21 585 | 0 | 2 | $-52 171 |
| John Northcott | SVP & Chief Commercial Officer | 16 maja 2022 S | 223 210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 5 września 2019 P | 107 668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16 maja 2019 S | 94 694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15 listopada 2017 A | 56 553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 5 lutego 2014 A | — | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 6 lutego 2013 A | 9 753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23 lutego 2009 A | — | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14 listopada 2008 M | 313 880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25 lutego 2008 A | 1 400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14 maja 2007 D | 6 600 | 0 | 0 | $0 |
| Diana Brainard | Dyrektor | 30 września 2025 A | 28 560 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | Dyrektor | 30 września 2025 A | 34 153 | 0 | 0 | $0 |
| Robert Chess | Dyrektor | 30 września 2025 A | 255 273 | 0 | 0 | $0 |
| Scott R Greer | Dyrektor | 30 września 2025 A | 303 574 | 0 | 0 | $0 |
| Roy A Whitfield | Dyrektor | 30 września 2025 A | 216 250 | 0 | 0 | $0 |
| Myriam Curet | Dyrektor | 19 września 2023 A | 27 418 | 0 | 0 | $0 |
| Karin Eastham | Dyrektor | 16 września 2022 A | 23 233 | 0 | 0 | $0 |
| Lutz Lingnau | Dyrektor | 22 września 2020 A | 35 800 | 0 | 0 | $0 |
| Christopher A Kuebler | Dyrektor | 27 września 2018 A | 45 250 | 0 | 0 | $0 |
| Dennis L Winger | Dyrektor | 21 sierpnia 2018 M | 42 750 | 0 | 0 | $0 |
| Joseph J Krivulka | Dyrektor | 19 września 2017 A | 82 000 | 0 | 0 | $0 |
| Susan Wang | Dyrektor | 20 listopada 2015 M | 20 000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | Dyrektor | 15 września 2009 A | 10 000 | 0 | 0 | $0 |
| Hoyoung Huh | Dyrektor | 2 grudnia 2008 A | — | 0 | 0 | $0 |
| Irwin Lerner | Dyrektor | 2 grudnia 2008 A | 10 000 | 0 | 0 | $0 |
| James B Glavin | Dyrektor | 4 września 2003 A | — | 0 | 0 | $0 |
| Masuoka K. Lorianne | — | 8 lutego 2011 A | — | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23 marca 2006 S | 87 991 | 0 | 0 | $0 |
| Ajay Bansal | — | 10 marca 2006 S | 5 166 | 0 | 0 | $0 |
| Melvin Perelman | — | 2 września 2004 A | — | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 1 akcja
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22 sierpnia 2005 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 28 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,14% | 50 876 NS | 31 maja 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 3,11% | 10 455 NS | 30 kwietnia 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,55% | 2 353 NS | 30 kwietnia 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,15% | 5 045 NS | 30 kwietnia 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,58% | 1 726 SH | 8 sierpnia 2026 | Dziennie |
| IHE · iShares Trust | 0,55% | 120 730 SH | 8 sierpnia 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 59 612 SH | 8 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | 0,14% | 278 376 SH | 8 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33 135 SH | 8 sierpnia 2026 | Dziennie |
| TMFX · RBB Fund, Inc. | 0,09% | 455 NS | 31 maja 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 877 973 SH | 8 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198 365 SH | 8 sierpnia 2026 | Dziennie |
| ISCV · iShares Trust | 0,07% | 6 414 SH | 8 sierpnia 2026 | Dziennie |
| SCHA · SCHWAB STRATEGIC TRUST | 0,04% | 151 830 NS | 31 maja 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 11 131 NS | 30 kwietnia 2026 | N-PORT |
| ISCB · iShares Trust | 0,03% | 1 294 SH | 8 sierpnia 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387 471 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,03% | 92 340 SH | 8 sierpnia 2026 | Dziennie |
| WSML · iShares Trust | 0,02% | 1 887 SH | 8 sierpnia 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3 096 SH | 8 sierpnia 2026 | Dziennie |
| IWN · iShares Trust | 0,02% | 32 466 SH | 8 sierpnia 2026 | Dziennie |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 6 903 NS | 31 maja 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 48 124 SH | 8 sierpnia 2026 | Dziennie |
| IWV · iShares Trust | 0,00% | 9 139 SH | 8 sierpnia 2026 | Dziennie |
| TILT · FlexShares Trust | 0,00% | 770 NS | 30 kwietnia 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 18 540 NS | 31 maja 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 075 430 SH | 8 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 837 SH | 8 sierpnia 2026 | Dziennie |